Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Medtronic
McKesson
Mallinckrodt
Colorcon

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

REVATIO Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Revatio patents expire, and what generic alternatives are available?

Revatio is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in REVATIO is sildenafil citrate. There are twenty drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

Drug patent expirations by year for REVATIO
Drug Prices for REVATIO

See drug prices for REVATIO

Recent Clinical Trials for REVATIO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Montefiore Medical CenterEarly Phase 1
University of Wisconsin, MadisonPhase 2
Hartford HospitalPhase 3

See all REVATIO clinical trials

Recent Litigation for REVATIO

Identify potential future generic entrants

District Court Litigation
Case NameDate
Natural Alternatives International, Inc. v. Woodbolt Distribution, LLC2011-12-21
PFIZER INC. v. HETERO DRUGS LTD.2011-07-28
Pfizer Inc. v. Watson Pharmaceuticals, Inc.2011-06-01

See all REVATIO litigation

Pharmacology for REVATIO

US Patents and Regulatory Information for REVATIO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer REVATIO sildenafil citrate FOR SUSPENSION;ORAL 203109-001 Aug 30, 2012 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer REVATIO sildenafil citrate SOLUTION;INTRAVENOUS 022473-001 Nov 18, 2009 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer REVATIO sildenafil citrate TABLET;ORAL 021845-001 Jun 3, 2005 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Baxter
Colorcon
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.